Evidence map›Paper›PMID 34846098›Full record

ArticleJournal of applied clinical medical physics2022

Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time.

Mikel Byrne, Ben Archibald-Heeren, Yunfei Hu, Amy Teh, Rhea Beserminji, Emma Cai, Guilin Liu, Angela Yates, James Rijken, Nick Collett and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07245745 (Prospective Clinical Study Comparing Patient-reported Outcomes Measurements), which is not on this map. Cited by 138 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07245745 narecruitingnot on this mapstarted 2026, after this paper: background citation

Prospective Clinical Study Comparing Patient-reported Outcomes Measurements (PROMS) After Adaptive or Conventional Radiotherapy in Prostate Cancer

TypeinterventionalSponsorCliniques universitaires Saint-Luc- Université Catholique de LouvainRan2026 to 2029Enrolled188ConditionsProstate CancerArmsRadiotherapy
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  2. Pooled it
  3. An in-house timer for ART-specific extra time in gynecologic pelvic online adaptive radiation therapy.Technical innovations & patient support in radiation oncology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Innovative radiotherapy approaches.ESMO gastrointestinal oncology · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mikel ByrneIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.ORCID https://orcid.org/0000-0003-2105-3964
Ben Archibald-HeerenIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Yunfei HuIcon Cancer Centre Gosford, Gosford, New South Wales, Australia.ORCID https://orcid.org/0000-0001-6121-8853
Amy TehIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Rhea BeserminjiIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Emma CaiIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Guilin LiuIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Angela YatesIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
James RijkenIcon Cancer Centre Windsor Gardens, Windsor Gardens, South Australia, Australia.
Nick CollettIcon Cancer Centre Wahroonga, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Trent AlandIcon Core Office, South Brisbane, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Varian Ethos system allows for online adaptive treatments through the utilization of artificial intelligence (AI) and deformable image registration which automates large parts of the anatomical contouring and plan optimization process. In this study, treatments of intact prostate and prostate bed, with and without nodes, were simulated for 182 online adaptive fractions, and then a further 184 clinical fractions were delivered on the Ethos system. Frequency and magnitude of contour edits were recorded, as well as a range of plan quality metrics. From the fractions analyzed, 11% of AI generated contours, known as influencer contours, required no change, and 81% required minor edits in any given fraction. The frequency of target and noninfluencer organs at risk (OAR) contour editing varied substantially between different targets and noninfluencer OARs, although across all targets 72% of cases required no edits. The adaptive plan was the preference in 95% of fractions. The adaptive plan met more goals than the scheduled plan in 78% of fractions, while in 15% of fractions the number of goals met was the same. The online adaptive recontouring and replanning process was carried out in 19 min on average. Significant improvements in dosimetry are possible with the Ethos online adaptive system in prostate radiotherapy.

Indexed as

Prostatic NeoplasmsRadiotherapy, Intensity-ModulatedArtificial IntelligenceHumansMaleOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-Assistedadaptive therapydeformable registrationmachine learning

Identifiers

PMID34846098
PMCPMC8803282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.